Stockreport

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

Elutia, Inc. - Class A  (ELUT) 
PDF EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 [Read more]